BioSpace News Archive

Inozyme Pharma, Inc. today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.

ABVC BioPharma, Inc. announced that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma for the Company’s CNS drugs with the indications of MDD and ADHD .

Tenaya Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of the company’s Investigational New Drug (IND) application to initiate clinical testing of TN-401.

Curis, Inc. today announced that the Company will release its third quarter 2023 financial results on Thursday, November 2, 2023 , at 8:00 a.m.

Zivo Bioscience, Inc. today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from 12:00 p.m. - 12:30 p.m. Eastern Daylight Time.

Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023.

Kye Pharmaceuticals Inc., a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA, a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine.

Immix Biopharma, Inc., announced that effective , Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.